In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CAR-T Commercialization Strategies: Views From Novartis And Kite

Executive Summary

At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.


Related Content

A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas
Iovance Biotherapeutics CEO On TIL Immunotherapy For Solid Tumors
Proving The Value Of Value-Based Deals
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Cell And Gene Therapies: Where Few Standard Rules Apply
Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS
Kite’s Axi-Cel CAR-T: No Adcomm, No Problem
Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
Novartis Woos Payers With Data Showing Entresto Earns Its Keep


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts